Financial Results, Quarterly Earnings Schedules, Marketing Authorizations, Completed Acquisitions, and New Drug Applications -

  Financial Results, Quarterly Earnings Schedules, Marketing Authorizations,
Completed Acquisitions, and New Drug Applications - Research Report on Johnson
                & Johnson, AbbVie, GSK, AstraZeneca, and Keryx

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 18, 2013

NEW YORK, October 18, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV), GlaxoSmithKline plc (NYSE:
GSK), AstraZeneca PLC (NYSE: AZN), and Keryx Biopharmaceuticals Inc. (NASDAQ:
KERX). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Johnson & Johnson Research Report

On October 15, 2013, Johnson & Johnson released its Q3 2013 results. Johnson &
Johnson registered sales of $17.6 billion in Q3 2013, up 3.1% YoY. Net
earnings attributable to Johnson & Johnson were $3.0 billion in Q3 2013, up
0.5% YoY. The Company reported diluted EPS of $1.04 in Q3 2013, down 1.0% YoY.
Commenting on the results, Alex Gorsky, Chairman and CEO of the Company, said,
"Our third-quarter results reflect the solid, demonstrable results in
achieving our near-term priorities while also advancing our longer term
strategic growth drivers." Gorsky continued, "Our key products and successful
new product launches delivered strong growth. We continue to progress our
pipelines with a number of regulatory approvals, the submission of new drug
applications, and execution of strategic collaborations. Our investments
further strengthen our ability to deliver sustainable growth and bring
meaningful innovations to patients and consumers." The Full Research Report on
Johnson & Johnson - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/07a8_JNJ]

--

AbbVie Inc. Research Report

On October 4, 2013, AbbVie Inc. (AbbVie) announced that it will release its Q3
2013 results before the market opens on Friday, October 25, 2013. AbbVie
reported that it will hold a live webcast of the quarterly earnings conference
call on the same day at 8:00 a.m. CT (9:00 a.m. ET). The Company also informed
that the live webcast can be accessed through its Investor Relations website,
and the archived edition of the call will be available after 11:00 a.m. CT.
The Full Research Report on AbbVie Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/273c_ABBV]

--

GlaxoSmithKline plc Research Report

On October 4, 2013, GlaxoSmithKline plc (GSK) announced the submission of a
variation to the Marketing Authorization to the European Medicines Agency
(EMA), for the use of Arzerra (ofatumumab) in combination with an
alkylator-based therapy for the treatment of CLL patients who have not
received prior treatment and are inappropriate for fludarabine-based therapy.
GSK reported that the submission is based primarily on results from an
international, multi-centre, randomised Phase III study of ofatumumab in
combination with chlorambucil versus chlorambucil alone in more than 400
patients with previously untreated CLL. The Full Research Report on
GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/2a35_GSK]

--

AstraZeneca PLC Research Report

On October 7, 2013, AstraZeneca PLC (AstraZeneca) announced that its global
biologics research and development arm, MedImmune, completed the acquisition
of Amplimmune on October 4, 2013. The Company said that MedImmune has acquired
100% of Amplimmune's shares for an initial consideration of $225 million and
deferred consideration of up to $275 million based on reaching predetermined
development milestones. AstraZeneca reported that the acquisition bolsters
MedImmune's oncology pipeline by obtaining multiple early-stage assets for its
immune-mediated cancer therapy (IMT-C) portfolio, including AMP-514, an
anti-programmed cell death 1 (PD-1) monoclonal antibody. AstraZeneca also
stated that other Amplimmune assets include multiple preclinical molecules
targeting the B7 pathways. The Full Research Report on AstraZeneca PLC -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/09cc_AZN]

--

Keryx Biopharmaceuticals Inc. Research Report

On October 8, 2013, Keryx Biopharmaceuticals Inc. (Keryx) announced that its
New Drug Application (NDA) for Zerenex (ferric citrate coordination complex)
has been accepted for filing by the US Food and Drug Administration (FDA). Ron
Bentsur, CEO of Keryx, said, "We are very pleased with the FDA's acceptance
for filing of our NDA for Zerenex, as this represents an important achievement
in the development of Zerenex. We believe that Zerenex has the potential to
make a meaningful difference in the lives of patients with chronic kidney
disease on dialysis, and we look forward to continuing to work with the FDA in
its review process of the Zerenex NDA." The Full Research Report on Keryx
Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/27d2_KERX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)